ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion...
HOUSTON, July 28, 2025 /PRNewswire/ -- Veriforce, a global leader in contractor risk management and safety compliance, and DISA Global Solutions, a premier provider...
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.
Submissions for Request for Information now open on SAM.gov
WASHINGTON, July 25, 2025 /PRNewswire/ -- The Transportation Security Administration (TSA) recently issued a Request for...
Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality, Reliability and Innovation
NASHVILLE, Tenn., July 23, 2025 /PRNewswire/ -- Matrix Medical...
Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
2024's drill program was highly successful at converting Inferred resources, upgrading and expanding Indicated resources – meeting the key objectives and providing a foundation...